Serotype-Specific Dengue Virus IgG Assay Using EDIII-Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil.

Dengue is the most prevalent arboviral disease globally, with Brazil currently experiencing a significant rise in cases. Dengue virus (DENV) typically co-circulates with other clinically and antigenically similar flaviviruses, such as Zika virus (ZIKV). The clinical diagnosis is difficult and accurate serological analysis represents an unmet challenge.

Elderly Individuals Exhibit Elevated Levels of Anti-Monkeypox Virus Antibodies Compared to Adults, Youth, and Children.

The variola virus, the causative agent of smallpox, has claimed more human lives than all other infectious diseases combined. Consequently, any epidemiological event involving related viruses (orthopoxviruses) triggers significant concern, as was the case with the pandemic rise of monkeypox virus (MPXV), the causative agent of monkeypox in 2022-2023. Smallpox vaccines, based on vaccinia virus antigens, are expected to provide cross-protection against MPXV.

The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population.

Several additional COVID-19 vaccine doses were administered in the Brazilian population to prevent the disease caused by the B.1.1.

Co-circulation of , , and serotype 1 of in Western Bahia, Brazil.

Chikungunya, mayaro, dengue, zika, and yellow fever are mosquito-borne viral diseases caused, respectively, by , (CHIKV and MAYV, respectively: : ), , (DENV, ZIKV, and YFV, respectively: : ). These viruses have an important epidemiological impact worldwide, especially in Brazil. Western Bahia is one of the less studied regions in that country regarding the circulation of these pathogens.

The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine.

A third vaccine dose against COVID-19 is already a reality in some countries around the world. In this study, we aimed to evaluate the effectiveness of the Brazilian immunization policy for COVID-19, which involves a booster shot. Participants ( = 210) provided serum samples, which were subjected to enzyme-linked immunosorbent assay (ELISA).